BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.
Published July 19, 2017 · Recall initiated: May 25, 2017
Summary
FDA records drug Class I recall D-0958-2017, published July 19, 2017 and initiated May 25, 2017. Recalling firm: AstraZeneca Pharmaceuticals, LP; Status: Terminated; Reported quantity: 40,368 bottles; Lot: Lot # JB5047, Exp 10/19. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
What to do
Voluntary: Firm initiated · Press Release
Get an email if BRILINTA has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BRILINTA
- Manufacturer
- AstraZeneca Pharmaceuticals, LP
- Distributor
- Nationwide in the USA and Puerto Rico to physician offices.
- Lot
- Lot # JB5047, Exp 10/19
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABrilinta ticagrelar tablets 60 mg 60 tablets Rx only NDC 0186-0776-60 Mfd. for: AstraZeneca LP, Wilmington, DEJune 2, 2021
- FDA0.9% Sodium Chloride Injection USP, 250 mL VIAFLEX Container bag, Rx only, Baxter Healthcare Corporation,July 19, 2017
- FDAEliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543July 19, 2017
- FDAPotassium Phosphate (USP) QS 0.9% Sodium Chloride (USP) 250 mL 15 mmol in NS 250mL Bag, Advanced Pharma, 9265July 19, 2017
- FDAPaliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis LaboratoriesJuly 19, 2017
- FDAPotassium Phosphate (USP) QS 0.9% Sodium Chloride (USP) 250 mL 30 mmol in NS 250mL Bag, Advanced Pharma, 9265July 19, 2017
Questions about this recall
Was BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08. recalled?
Yes. FDA published recall D-0958-2017 on July 19, 2017. Reported hazard: Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
What should I do if I have this product?
Voluntary: Firm initiated · Press Release
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BRILINTA.